Misplaced Pages

InNexus Biotechnology

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (November 2021)
This article includes a list of references, related reading, or external links, but its sources remain unclear because it lacks inline citations. Please help improve this article by introducing more precise citations. (March 2014) (Learn how and when to remove this message)
(Learn how and when to remove this message)
InNexus Biotechnology Inc.
Company typePublic
Traded asNEX: IXS.H
IndustryBiotechnology
Founded2001, British Columbia, Canada
HeadquartersPrincipal Management formerly in Chandler, Arizona, United States.
Key peopleJeff Morhet, Former Chairman and CEO
David Petulla, Former CFO
Thomas Kindt, Former Chief Scientific Officer
ProductsDXL625 (CD20) for prospective treatment of Non-Hodgkin’s Lymphoma, preclinical stage,
DXL702 (HER2/neu) for prospective treatment of breast cancer, preclinical stage.
Number of employees0 (2012)

InNexus Biotechnology, Inc.. was a drug company based in British Columbia, Canada. InNexus was founded in 2001 and became a publicly traded corporation in 2003 on the TSX Venture Exchange. On 2009-12-30, the company filed a Form 15-F with the U.S. Securities and Exchange Commission (SEC) to voluntarily deregister its common stock under the Securities Exchange Act of 1934 and continue its primary listing on the TSX Venture Exchange under the symbol of IXS; it is no longer listed on the TSX Venture Exchange. IXS was developing what they refer to as DXLA- or DXL-modified antibodies, wherein certain autophilic peptides are integrated with a monoclonal antibody. The DXL-modified antibodies have been shown to have enhanced binding affinity and, as a potential result, greater potency for use as a therapy to fight cancer and higher signal strength for use as a diagnostic for detecting cancer versus an unmodified antibody.

References

Categories: